About US
Contact us
-
Johnson & Johnson pledges 100M coronavirus vaccine doses to U.S. for $10 eachWith leading COVID-19 vaccines in late-stage testing, companies have been inking supply deals with the U.S. government for a quick rollout if their programs succeed. Now, Johnson & Johnson is get2020/8/4
-
Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivalsAs companiesworldwide grapple with sales challenges from the COVID-19 pandemic, Amgen is getting a boost from its newly acquired immunology blockbuster Otezla. The medicine, picked up from Celgene2020/7/30
-
Roche arthritis drug Actemra flunks COVID-19 study, but remdesivir combo data awaitYet anotherattempt at repurposing existing drugs for COVID-19 has fallen short. Roche’s arthritis med Actemrafailed tobeat placebo at significantly improving clinical status among patients with se2020/7/30
-
Pfizer CEO: We may cut jobs, backpedal on expansions if Trump's pricing orders take effectPresident Donald J. Trump's recent spate of executive orders targeting U.S. drug prices has received heaps of scorn from the pharmaceutical industry and its lobbyists. Now, Pfizer says Trump's mandat2020/7/29
-
Camera maker Kodak dives into drug manufacturing with $765M federal loanWith COVID-19 straining international relations over the supply of needed generic medicines, the U.S. has scrambled to pump up domestic production of those key drugs. Now, the government is making a2020/7/29
-
Vyndaqel, Ibrance boost Pfizer as it eyes COVID-19 vaccine launch this yearAdd another name to the list of pharmas reporting sales declines amid the pandemic. But this company, Pfizer, is still dialing up its full-year revenue expectations—not that it’s counting any contrib2020/7/28
-
Pharma execs, upset by Trump's drug pricing executive orders, refuse White House meetingPresident Donald Trump seems to have hit a nerve with his Friday executive orders on drug pricing. As drug companies work to battle the pandemic, executives declined to attend a White House meeting t2020/7/28
-
AstraZeneca's Farxiga backs up kidney disease trial stop with new top-line dataAstraZeneca has shaken upthe lucrative heart failure market with diabetes med Farxiga after a major approval earlier this year. But in kidney disease, another blockbuster market, Farxiga also sports2020/7/27
-
Pfizer could earn $15B-plus in COVID-19 vaccine sales: analystOn the heels of Pfizer's $1.95 billion COVID-19 vaccine deal with the U.S. government, one analyst says the drugmaker could earn many more billions in revenue on its potential vaccine—if the program2020/7/27
-
Pfizer, BioNTech's U.S. supply deal price tag leaves room for 'decent' profit on COVID-19 shot: analystThe Trump administration made a major splash in the race for a COVID-19 vaccine this week with its $1.95 billion supply deal for Pfizer and BioNTech's shot. With 100 million doses due in the deal, th2020/7/24